Protalix BioTherapeutics (PLX) Gains from Sales and Divestitures (2020 - 2025)
Protalix BioTherapeutics' quarterly Gains from Sales and Divestitures came in at $687232.0 in Q4 2025, down 30.74% year-on-year from $992313.0 in Q4 2024, and up 1198.87% quarter-over-quarter from $52910.0 in Q3 2025.
Protalix BioTherapeutics has reported Gains from Sales and Divestitures for 6 years, with the latest figure at $687232.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 30.74% year-over-year to $687232.0; the trailing twelve-month figure through Dec 2025 stood at $687232.0 (down 30.74% YoY), and the FY2025 full-year result was $687232.0, down 30.74% from the prior year.
- Gains from Sales and Divestitures for Q4 2025 stood at $687232.0, up from $52910.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $992313.0 in Q4 2024, with the low at $52910.0 in Q3 2025.
- Average Gains from Sales and Divestitures over 5 years is $552368.2, with a median of $588199.0 recorded in 2023.
- Year-over-year, Gains from Sales and Divestitures soared 456.0% in 2022 and plunged 47.18% in 2023.
- Tracing PLX's Gains from Sales and Divestitures over 5 years: stood at $166553.0 in 2021, then soared by 456.0% to $926035.0 in 2022, then slumped by 47.18% to $489166.0 in 2023, then surged by 102.86% to $992313.0 in 2024, then tumbled by 30.74% to $687232.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $687232.0 (Q4 2025), $52910.0 (Q3 2025), and $992313.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 687,232.00 |
| Dec 31, 2025 | 687,232.00 |
| Sep 30, 2025 | 52,910.00 |
| Sep 30, 2025 | 52,910.00 |
| Dec 31, 2024 | 992,313.00 |
| Dec 31, 2024 | 992,313.00 |
| Dec 31, 2023 | 489,166.00 |
| Dec 31, 2023 | 489,166.00 |
| Dec 31, 2022 | 926,035.00 |
| Dec 31, 2022 | 926,035.00 |
| Dec 31, 2021 | 166,553.00 |
| Dec 31, 2021 | 166,553.00 |
| Dec 31, 2020 | 69,493.00 |
| Dec 31, 2020 | 69,493.00 |